Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance

Osimertinib, third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), has been approved in the US and EU for the treatment of EGFR mutant T790M-positive non-small cell lung cancer (NSCLC) patients resistant to first- or second-generation EGFR-TKIs, such as gefitinib, e...

Full description

Saved in:
Bibliographic Details
Published in:Transl Lung Cancer Res
Main Authors: Minari, Roberta, Bordi, Paola, Tiseo, Marcello
Format: Artigo
Language:Inglês
Published: AME Publishing Company 2016
Subjects:
Review Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5233880/
https://ncbi.nlm.nih.gov/pubmed/28149764
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr.2016.12.02
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items